David F McDermott

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint PD-1 as a potential target in cancer therapy
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Cancer Med 2:662-73. 2013
  2. doi request reprint Immune therapy for kidney cancer: a second dawn?
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center Department of Medicine, Harvard Medical School, Boston, MA, USA
    Semin Oncol 40:492-8. 2013
  3. doi request reprint Immunotherapy of metastatic renal cell carcinoma
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MS 428, Boston, MA 02215, USA
    Cancer 115:2298-305. 2009
  4. doi request reprint Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
  5. ncbi request reprint Immunotherapy and targeted therapy combinations in renal cancer
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Curr Clin Pharmacol 6:207-13. 2011
  6. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response
    David F McDermott
    Beth Israel Deaconess Medical Center and the Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Semin Oncol 33:583-7. 2006
  7. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Genitourin Cancer 5:114-9. 2006
  8. doi request reprint Immunotherapy of metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, and Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Cancer J 14:320-4. 2008
  9. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
  10. ncbi request reprint Application of IL-2 and other cytokines in renal cancer
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02186, USA
    Expert Opin Biol Ther 4:455-68. 2004

Detail Information

Publications45

  1. doi request reprint PD-1 as a potential target in cancer therapy
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Cancer Med 2:662-73. 2013
    ..If subsequent investigations confirm the initial results, it is conceivable that agents blocking the PD-1/PD-L1 pathway will prove valuable additions to the growing armamentarium of targeted immunotherapeutic agents. ..
  2. doi request reprint Immune therapy for kidney cancer: a second dawn?
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center Department of Medicine, Harvard Medical School, Boston, MA, USA
    Semin Oncol 40:492-8. 2013
    ..Novel approaches including inhibition of immune checkpoints has entered clinical testing in RCC. ..
  3. doi request reprint Immunotherapy of metastatic renal cell carcinoma
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MS 428, Boston, MA 02215, USA
    Cancer 115:2298-305. 2009
    ..Improvements in patient selection, novel agents, and combination therapy will be required to optimize the benefits of immunotherapy in metastatic RCC as the list of effective therapies grows...
  4. doi request reprint Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    ..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma...
  5. ncbi request reprint Immunotherapy and targeted therapy combinations in renal cancer
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Curr Clin Pharmacol 6:207-13. 2011
    ....
  6. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response
    David F McDermott
    Beth Israel Deaconess Medical Center and the Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Semin Oncol 33:583-7. 2006
    ..This year, investigators will launch a clinical trial designed to prospectively determine if patients who are more likely to respond to high-dose IL-2 can be identified prior to starting therapy...
  7. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Genitourin Cancer 5:114-9. 2006
    ..This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated...
  8. doi request reprint Immunotherapy of metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, and Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Cancer J 14:320-4. 2008
    ..As the list of effective therapies for metastatic RCC grows, improvements in patient selection and more "targeted" approaches will be required to optimize the benefits of cytokine therapy in metastatic RCC...
  9. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  10. ncbi request reprint Application of IL-2 and other cytokines in renal cancer
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02186, USA
    Expert Opin Biol Ther 4:455-68. 2004
    ....
  11. doi request reprint The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MS 428, Boston, MA 02215, USA
    Med Oncol 26:13-7. 2009
    ....
  12. doi request reprint Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data
    David F McDermott
    Beth Israel Deaconess Medical Center, Department of Medicine, Division of Hematology Oncology, 375 Longwood Avenue, MS 428, Boston, MA 02215, USA
    Cancer Treat Rev 36:216-23. 2010
    ..Collectively, these studies allow the role of bevacizumab-based therapy to be defined in the context of a new and evolving algorithm for the treatment of patients with advanced RCC...
  13. ncbi request reprint Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 32:181-5. 2009
    ..The assumption that IL-2 therapy can be safely administered after TKI therapy may not be valid. Further examination of the safety of this sequential approach is necessary and more cautious patient selection seems warranted...
  14. doi request reprint Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    Eur Urol 59:856-62. 2011
    ..Since these therapies can induce tumor necrosis and minimal tumor shrinkage, Response Evaluation Criteria in Solid Tumors (RECIST) may not be optimal for predicting clinical outcome...
  15. doi request reprint The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy
    Toni K Choueiri
    Kidney Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 185:60-6. 2011
    ..Vascular endothelial growth factor targeted therapy is a standard of care in patients with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of novel agents remains poorly defined...
  16. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
    ..However, a major toxicity is vascular leak syndrome (VLS). We previously reported elevated serum angiopoietin 2 (Ang2) in septic patients with vascular leak and hypothesized that Ang2 might also contribute to HDIL2 VLS...
  17. ncbi request reprint Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
    Jared A Gollob
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 21:2564-73. 2003
    ....
  18. ncbi request reprint A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
    Uday B Dandamudi
    Dartmouth Hitchcock Medical Center, Lebanon, NH Dana Farber Cancer Institute, Harvard School of Public Health Beth Israel Deaconess Medical Center Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Vanderbilt University Medical Center, Nashville, TN Loyola University Medical Center, Maywood, IL Georgetown Lombardi Comprehensive Cancer Center, Washington, DC St Luke s Roosevelt Hospital Center, New York, NY Earle A Chiles Research Institute Providence Cancer Center, Portland, OR Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
    J Immunother 36:490-5. 2013
    ..Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone. ..
  19. ncbi request reprint A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 8:3075-81. 2002
    ..Tumor staging included torso computed tomography scans and brain magnetic resonance imaging pretreatment, after cycle 4 and then every 3 months for 2 years. Torso computed tomography scans were also performed after cycle 2...
  20. pmc Improved survival with ipilimumab in patients with metastatic melanoma
    F Stephen Hodi
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:711-23. 2010
    ....
  21. doi request reprint Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    Cancer 116:5219-25. 2010
    ..In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)-targeted therapy in this distinct subtype of RCC...
  22. pmc Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 115:2247-51. 2009
    ..The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow...
  23. ncbi request reprint Update on the application of interleukin-2 in the treatment of renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:716s-720s. 2007
    ..As the list of effective therapies for metastatic renal cell carcinoma grows, improvements in patient selection will be necessary to ensure that patients who might attain a durable remission with IL-2 will not miss this opportunity...
  24. pmc Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 31:181-6. 2013
    ..Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC...
  25. doi request reprint Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
    Aymen A Elfiky
    Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    Urol Oncol 29:756-63. 2011
    ..To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib...
  26. ncbi request reprint Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    Melissa P Upton
    Beth Israel Deaconess Medical Center, Department of Pathology, Boston, MA 02215, USA
    J Immunother 28:488-95. 2005
    ..Investigation of other tumor-related predictors of IL-2 responsiveness is warranted...
  27. ncbi request reprint Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:667s-670s. 2007
    ....
  28. pmc Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
    Fabio A B Schutz
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 14:81-7. 2013
    ..Germline genetic polymorphisms might affect the risk of recurrence in patients with localised renal-cell carcinoma. We investigated the association between genetic polymorphisms and recurrence of renal-cell carcinoma...
  29. ncbi request reprint Immunotherapy for metastatic renal cell carcinoma
    David F McDermott
    DF HCC Renal Cancer Program, Beth Israel Deaconess Medical Center, Boston, MA, USA
    BJU Int 99:1282-8. 2007
  30. doi request reprint Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer
    Shuchi S Pandya
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, East Campus, Boston, MA 02215, USA
    BJU Int 108:E245-9. 2011
    ..To investigate the role of adding gemcitabine at the time of sunitinib failure in patients with metastatic renal cell cancer (mRCC)...
  31. doi request reprint The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
    Fabio A B Schutz
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Eur Urol 65:723-30. 2014
    ..Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy...
  32. ncbi request reprint Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy
    Ken Wyman
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer 106:2005-11. 2006
    ..Signal transduction via c-kit, PDGFR-alpha, and PDGFR-beta has been demonstrated in malignant melanoma...
  33. doi request reprint Novel immunotherapies in GU malignancies
    Alexandra Drakaki
    Beth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA
    Curr Oncol Rep 15:224-31. 2013
    ..This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate...
  34. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  35. doi request reprint The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma
    Jessica M Clement
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Clin Genitourin Cancer 7:E7-9. 2009
    ....
  36. doi request reprint Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma
    Kathryn A Bylow
    Department of Medicine, Section of Hematology Oncology, University of Chicago, IL, USA
    Clin Genitourin Cancer 7:39-42. 2009
    ..Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients...
  37. doi request reprint Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics
    Alexandra Bailey
    Beth Israel Deaconess Medical Center, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Cancer J 19:348-52. 2013
    ..Ongoing clinical trials hope to define patients who will benefit based on predictive biomarkers. Immune checkpoint inhibitors may play a key role in the future of management of solid tumors including kidney cancer. ..
  38. doi request reprint Immunotherapy for renal cell carcinoma
    Jacalyn Rosenblatt
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 25:793-812. 2011
    ..This review describes how improvements in patient selection, combination therapy, and investigational agents might expand and better define the role of immunotherapy in metastatic RCC...
  39. doi request reprint Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 358:2389-96. 2008
  40. ncbi request reprint Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
    Allison Ackerman
    Department of Medicine, Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Cancer 120:1695-701. 2014
    ..This retrospective analysis describes the outcomes of patients treated with either BRAFi before IT or IT before BRAFi...
  41. pmc Management of metastatic renal cell carcinoma in patients with poor prognosis
    Andrea Bullock
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Cancer Manag Res 2:123-32. 2010
    ..Ongoing translational research efforts may help to define novel treatment approaches specific for patients with metastatic RCC and poor prognostic features...
  42. ncbi request reprint Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy
    Scott R Floyd
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 23:3138-40. 2005
  43. ncbi request reprint More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma
    David F McDermott
    J Clin Oncol 25:3791-3. 2007
  44. ncbi request reprint Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3958-64. 2007
    ..A recommended dose and safety profile for the combination of temsirolimus and interferon alfa (IFN) were determined in patients with advanced RCC...
  45. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...